Please take a moment and make a financial contribution to TheFunded. If we have helped you, help us with resources to further grow the both the site and our entrepreneur training program, The Founder Institute.

Coker Capital Partners CERTIFIED

Firm Rating:

Firm Homepage:

FIRM OVERVIEW: Medium Private VC founded in 2005 based out of Alpharetta, USA (US East)

FIRM DESCRIPTION: Coker Capital Partners is the private equity and corporate finance arm of the Coker Group, a global healthcare firm specializing in financial advisory, strategy consulting and technology solutions for healthcare sector businesses. Coker Capital focuses on early stage venture investments and later stage private equity financings in the healthcare sector. The firm's founders and Directors come from management at The Coker Group, and as such we bring years of experience working within the healthcare industry and leveraging our resources to assist new ventures with navigating challenges in this sector.

Posted by
oriole
on 2009-02-04

PUBLIC:

Our early stage technology company has made its initial pitch and begun discussions with Coker Capital. We have been impressed with the "smart capital" potential of Coker. That is, we believe that Coker's health care consulting business makes their potential investment to include expertise highly beneficial for a company involved in bioengineering R&D like ours. We have been impressed with Mark Reiboldt's ability to rapidly grasp our technology and business model. Coker appears to be an excellent fit for health sciences companies that need angel size investments with more value-added industry knowledge.

Posted by
shampton
on 2008-08-25

PUBLIC:

We just closed our seed round with Coker. I have been quite happy working with Mark and with John. The fund is new, and TheraKine doesn't fit into the usual box, so it took about five months from pitch to close. If you are in the South East looking for early phase med-tech money, you should talk to them, they aren't part of the Secret Handshake Club that used to dominate Atlanta biotech. I like that they are willing to get in very early with smaller amounts: innovators with promising ideas should definitely give them a call.